If you are wondering whether ResMed is still attractive after its strong run, or if the market has already priced in the upside, this article will help you cut through the noise and focus on what the ...

ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and ...

ResMed Inc. (NYSE:RMD) released its Q4 FY2025 earnings presentation on July 31, 2025, revealing robust financial performance despite a challenging macroeconomic environment. The global leader in ...

ResMed has seen its fair value estimate edge up slightly from $291.86 to $295.13, as recent improvements in margin expectations have contributed to this change. This modest increase comes amid ongoing ...

Fractus, a company specializing in geometry-based antenna technology and IP licensing, has filed a patent infringement suit against respiratory leader ResMed. The complaint was filed in the United ...

ResMed plans to sign a lease for an about 446,500-square-foot building on Collins Road in Greenwood. The company is seeking a nearly $500,000 three-year tax break from the Greenwood City Council.

Resmed Inc (NYSE:RMD) reported better-than-expected earnings for the second quarter on Thursday. The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of ...

Resmed announced that it will release its financial and operational results for the fourth quarter of fiscal year 2025 on July 31, 2025, after the market closes. Following the release, management will ...

ResMed has appointed Salli Schwartz as the new Chief Investor Relations Officer, effective April 21, 2025. Schwartz brings over two decades of experience from roles in finance at health tech and ...

ResMed, a company known for medical devices like CPAP machines, today announced the launch of the Kontor Head Strap, a new accessory designed for the Vision Pro. The Kontor Head Strap was created to ...

April 25 (Reuters) - ResMed (RMD.N), opens new tab beat Wall Street estimates for quarterly profit on Wednesday due to strong demand for its sleep apnea devices, sending shares 9% higher in extended ...

ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter: These 10 analysts have an average price target of $231.3 versus the current price of ResMed at $141.0, implying ...